Citigroup
FULC icon

Citigroup’s Fulcrum Therapeutics FULC Stock Holding History

Citigroup’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Buy
62,774
+39,339
+168% +$239K ﹤0.01% 4271
2026
Q1 		$180K Sell
23,435
-43,667
-65% -$405K ﹤0.01% 4050
2025
Q4 		$759K Buy
67,102
+66,384
+9,246% +$676K ﹤0.01% 3316
2025
Q3 		$6.61K Sell
718
-20,298
-97% -$147K ﹤0.01% 5146
2025
Q2 		$145K Sell
21,016
-16,813
-44% -$89.9K ﹤0.01% 4221
2025
Q1 		$109K Sell
37,829
-11,893
-24% -$43.7K ﹤0.01% 4555
2024
Q4 		$234K Sell
49,722
-24,981
-33% -$92.2K ﹤0.01% 4324
2024
Q3 		$267K Buy
74,703
+51,912
+228% +$385K ﹤0.01% 4147
2024
Q2 		$141K Sell
22,791
-155,773
-87% -$1.18M ﹤0.01% 4051
2024
Q1 		$1.69M Sell
178,564
-106,734
-37% -$953K ﹤0.01% 2573
2023
Q4 		$1.93M Buy
285,298
+196,109
+220% +$870K ﹤0.01% 2270
2023
Q3 		$396K Buy
89,189
+81,286
+1,029% +$355K ﹤0.01% 3232
2023
Q2 		$26.1K Buy
7,903
+6,193
+362% +$18.2K ﹤0.01% 4892
2023
Q1 		$4.87K Sell
1,710
-43
-2% -$385 ﹤0.01% 4950
2022
Q4 		$12.8K Sell
1,753
-167
-9% -$1.09K ﹤0.01% 4762
2022
Q3 		$16K Sell
1,920
-1,820
-49% -$13K ﹤0.01% 4816
2022
Q2 		$18K Sell
3,740
-25,488
-87% -$249K ﹤0.01% 5058
2022
Q1 		$691K Sell
29,228
-11,205
-28% -$159K ﹤0.01% 3283
2021
Q4 		$715K Buy
40,433
+33,118
+453% +$656K ﹤0.01% 3558
2021
Q3 		$206K Buy
7,315
+396
+6% +$7.5K ﹤0.01% 4102
2021
Q2 		$73K Buy
6,919
+5,178
+297% +$52.3K ﹤0.01% 4640
2021
Q1 		$21K Sell
1,741
-1,851
-52% -$22.9K ﹤0.01% 5217
2020
Q4 		$42K Buy
3,592
+2,905
+423% +$32.8K ﹤0.01% 6167
2020
Q3 		$5K Sell
687
-1,050
-60% -$12.6K ﹤0.01% 7008
2020
Q2 		$32K Sell
1,737
-1,942
-53% -$30.6K ﹤0.01% 6274
2020
Q1 		$44K Buy
3,679
+2,767
+303% +$44.3K ﹤0.01% 6076
2019
Q4 		$15K Buy
912
+673
+282% +$6.43K ﹤0.01% 7053
2019
Q3 		$2K Buy
+239
New +$2.64K ﹤0.01% 7539

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's FULC Position: Q2 2026 in Review

Citigroup increased its Fulcrum Therapeutics (FULC) stake by 168% in Q2 2026, buying an estimated $239K and bringing the position to 62,774 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #4271.

Citigroup first reported a position in FULC in Q3 2019 and has held it in 28 quarters since. The position peaked at $1.93M in Q4 2023. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Citigroup held 62,774 shares of Fulcrum Therapeutics worth $230K as of Q2 2026.
  • Citigroup bought 39,339 Fulcrum Therapeutics shares in Q2 2026, an estimated $239K.
  • Fulcrum Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4271 holding.
  • Citigroup first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Citigroup's Fulcrum Therapeutics position peaked at $1.93M in Q4 2023.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.